

PRESS RELEASE

EAACI presents the European Declaration on Allergen Immunotherapy

Istanbul/Zurich – 13 June – The European Academy of Allergy and Clinical Immunology, EAACI, has presented the *European Declaration on Allergen Immunotherapy* during the annual EAACI Congress. This document aims to provide a robust statement on the use of immunotherapy, its availability for allergic patients, and the need for resources to fund relevant research.

The *European Declaration on Allergen Immunotherapy* has been presented for the first time during the 30th EAACI Congress, which is taking place in Istanbul. During 2011, EAACI is celebrating the 100 Years of Immunotherapy. One century ago, in 1911, Leonard Noon published in *The Lancet* the first original paper describing the use of allergen extract injections to treat hay fever. To celebrate this anniversary, EAACI has developed a number of initiatives, including this pivotal document entitled *European Declaration on Allergen Immunotherapy*.

Even though Immunotherapy could be the most rewarding field in terms of return, translational value and European integration, and a field in which Europe is recognised as a worldwide leader, it has not yet received adequate attention from European institutions or research funding bodies. "Immunotherapy can free patients from their severe symptoms. I believe Europe would win a lot by taking advantage of this treatment" said Prof Nikolaos Papadopoulos, EAACI Secretary General. Evaluation and surveillance of the full cost of allergic diseases are still lacking and impaired by the variety of health systems across Europe.

EAACI would like to call upon Europe's policy-makers to coordinate actions and improve individual and public health in allergy by:

- Promoting immunotherapy awareness
- Updating national healthcare policies to support allergen immunotherapy
- Prioritising funding for immunotherapy research
- Monitoring the macroeconomic and health economic parameters of allergy
- Streamlining medical disciplines and specialties

EAACI believes that the effective implementation of the above policies has the potential for a major positive impact on European Health & Well-Being in the next decade.

If you would like to see the *European Declaration on Allergen Immunotherapy*, please click [here](#).

About EAACI :

EAACI - The European Academy of Allergy and Clinical Immunology is a non-profit organisation active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and



clinical immunology. It includes 6'500 members from 107 countries, as well as 41 National Allergy Societies.

Throughout 2011, EAACI will develop different activities to celebrate the 100th anniversary of immunotherapy in Allergy, which will aim at increasing the knowledge in this field among healthcare professionals, increase awareness in the general population, and finally, promote the availability of immunotherapy for allergic patients.

For further information:

EAACI 2011 Press Center

Elaine Snell (English)
Tel.: +44 (0)20 7738 0424, Mobile: +44 (0)7973 953 794
elaine@snell-communications.net
Snell Communications Ltd, UK www.snell-communications.net

Eren Akyurt (Turkish)
Tel Mobile +90 (0)544 344 5800
ernakyurt@gmail.com
Gülçin Yılmaz İzel (Turkish)
Tel +90 (0)212 356 09 09 or Mobile +90 (0)532 244 46 29
gulcinyilmaz@3diletisim.com
3D Communication Services, Turkey www.3diletisim.com

Direct Tel.: EAACI Press Office *from 11-15 June 2010 only*: +90 212 373 99 15

EAACI Headquarters

Head of Communications
Panthea Sayah
Genferstrasse 21
8002 Zurich
Switzerland
Tel.: +41 44 205 55 33
Fax: +41 44 205 55 39
Mobile: +41 79 551 99 48
E-mail: panthea.sayah@eaaci.org
Internet: www.eaaci.net